SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending due to its dedicated community and consistent growth over the past nine months, setting new all-time highs. The community is energized by a current buy contest and anticipates increased exposure with an upcoming listing, as well as an airdrop. Many believe $BROKE.X is undervalued and poised for a significant breakout, emphasizing its resilience and potential in the altcoin space.

Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain’s ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational portable neuromodulation stimulator, that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded on March 13, 2014 and is headquartered in Newtown, PA.

Helius Medical Technologies Inc - Ordinary Shares - Class A

Helius Medical Technologies Inc

HSDT is trending due to positive trial results for its PoNS device in stroke rehabilitation, with plans for FDA submission under Breakthrough Device Designation driving significant pre-market activity. The community is actively discussing potential short squeezes and the impact of the news on the company's future, while also noting the history of reverse splits and dilution. Traders are weighing the potential for a sustained run against the risks associated with the company's past performance and cash burn.

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Atyr Pharma Inc

aTyr Pharma, Inc

Anticipation is building around $ATYR as the mid-September data release window approaches, with discussion focused on the potential outcome of the Phase 3 trial and its impact on the company's future. Community members are weighing the possibility of positive results, a short squeeze, and potential price targets, while others express concerns about trial design, historical performance, and potential downside risks. The stock is experiencing high volatility and options activity as traders position themselves ahead of the highly anticipated news.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla ($TSLA) is trending amid rising Q3 delivery expectations and increased energy storage discussion. Community chatter highlights Barclays raising delivery expectations, robotics potential, and the cult-like following the stock commands. Some caution remains due to ending tax credits and potential bank target revisions.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia ($NVDA) is trending amid news of China investigating potential antitrust violations related to a past acquisition, sparking concerns about market access and potential penalties. The community debates the significance of this development, with some viewing it as an opportunity to buy the dip while others express concerns about the stock's vulnerability to negative China-related headlines and potential broader market impacts. Despite the uncertainty, some remain optimistic about Nvidia's long-term prospects, citing its leadership in AI and strong fundamentals.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending as investors discuss its high short interest and potential for a squeeze, with some citing the upcoming Rumble Wallet launch and the Northern Data acquisition as possible catalysts. JD Vance's exclusive on the platform and overall ties to prominent figures are also fueling community speculation. Despite some frustration with the stock's performance, bulls remain optimistic about its long-term potential, particularly with its connections to crypto and a shift towards alternative media.

Asset Entities, Inc. engages in providing social media marketing and content delivery services. It offers its services to Discord, TikTok, and other social media platforms. It also designs, develops and manages servers for communities on Discord. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani and Kyle Fairbanks on August 1, 2020 and is headquartered in Dallas, TX.

Asset Entities Inc - Ordinary Shares - Class B

Asset Entities Inc.

Asset Entities (ASST) is trending due to its recent merger with Strive and a strategic shift towards Bitcoin asset management, igniting discussions about a potential short squeeze. The community is focused on the high short interest, borrow fees, and the impact of the CUSIP change on trading availability. Some traders are expressing frustration over the inability to buy shares on certain platforms, while others remain optimistic about a potential surge.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending amid discussions about its potential as the 'next NVDA' and speculation around potential acquisition bids from major tech players. Community members are actively debating the company's long-term prospects, partnerships, and whether its valuation aligns with its growth potential. The stock is also gaining traction from news regarding a UK quantum tech pact and upcoming presentations at the Quantum World Congress.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, Defense and New Markets. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The New Markets segment includes development, manufacture and sales of small modular reactors (SMRs) and new electrical power solutions. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

Rolls-Royce Holding PLC (ADR)

Rolls-Royce is trending due to positive sentiment around nuclear energy deals and potential entry into the US SMR market. Community members are discussing the UK's commitment to nuclear expansion and anticipating further news from upcoming industry events. Increased defense spending and potential partnerships related to AI data centers are also driving interest in the stock.

BlackRock Institutional Trust Company N.A. - iShares Semiconductor ETF

iShares Semiconductor ETF

SOXX is trending due to a mix of factors, including reactions to Nvidia's potential to resume AI chip sales in China and overall optimism in the semiconductor sector. Community discussions revolve around SOXX's technical indicators, potential pullbacks, and strategies involving leveraged ETFs like SOXL and SOXS. Broader market context includes the AI boom, geopolitical tensions, and upcoming earnings reports from major semiconductor companies.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Retail chatter around UnitedHealth Group picked up late Sunday after a report said the insurer had sought meetings with U.S. President Donald Trump as it faces criminal and civil probes into its Medicare Advantage business and federal payment changes that have cut into results.&nbsp;The Wall Street Journal&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/business/unitedhealth-is-spending-big-on-trump-allies-to-fix-its-washington-problems-8ca64351">noted</a> that no meeting with Trump has been secured, but UnitedHealth has already spoken with senior Justice Department officials, including Attorney General Chief of Staff Chad Mizelle, in a rare early-stage discussion about government investigations.CEO Stephen Hemsley, who returned to the top role in May, has also reportedly met White House Chief of Staff Susie Wiles and separately dined with Medicare chief Chris Klomp, where billing policies and supplemental benefits were discussed, the report said.&nbsp;<a href="https://stocktwits.com/symbol/UNH">UnitedHealth</a> has lost about 40% of its market value since April and posted a 30% drop in June-quarter profit, its first decline in more than three years, amid new Medicare billing rules and regulatory scrutiny.The company has doubled lobbying outlays to $7.7 million in the first half of 2025, disclosure filings show,&nbsp;making it a record spending by the insurer.&nbsp;It has apparently turned to Trump-linked&nbsp;allies, including fundraiser Brian Ballard, former Justice Department official Jesse Panuccio, and Trump’s personal lawyer Robert Giuffra, who replaced a prior team of attorneys at WilmerHale. Ballard’s firm has become UnitedHealth’s highest-paid outside lobbyist.UnitedHealth, which generated more than $100 billion from Medicare Advantage last year, has said it is cooperating with federal requests and remains confident in its practices. The regulatory overhang comes as Medicare chief Mehmet Oz has vowed to crack down on billing tactics across the industry, intensifying investor concern about the company’s most profitable business line.UnitedHealth won some relief in August when the Justice Department cleared its long-delayed $3.3 billion acquisition of home-health provider Amedisys after divestitures.On Stocktwits, retail sentiment was ‘bullish’ amid ‘high’ message volume.One user said they expect UnitedHealth shares to test $380 this week, pointing to Trump and his allies as a major factor, adding that the stock is “not just recovering but entering the game all over again big time.”<stembedurl>https://stocktwits.com/MomentumWins/message/628641407</stembedurl>Another user noted that CEO Stephen Hemsley is “doing what he does best” by getting the company back on track after meeting with White House Chief of Staff Susie Wiles and Medicare official Chris Klomp.&nbsp;They described the outlook as “very bullish,” citing recent investor meetings and the appointment of new CFO Wayne DeVeydt, and suggested the stock could push above $400.<stembedurl>https://stocktwits.com/DerekQuick/message/628632142</stembedurl>UnitedHealth’s stock has declined 29.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone displays the logo of UnitedHealth Group Incorporated. (Photo illustration by Cheng Xin/Getty Images)

UnitedHealth Pushes For Trump Meeting As DOJ Probe Deepens, Doubles Down On Lobbying — Retail Traders Remain ‘Bullish’

The company’s CEO, Stephen Hemsley, has met senior White House and Medicare officials while also hiring Trump-linked lobbyists to navigate regulatory scrutiny.

Equity

Elevance Health Shrinks to Grow Stronger: From Part D to Plan B?

ELV exits Part D and trims Medicare Advantage markets, betting on stronger-margin plans to protect profitability.

CVS Health Makes Headway in Stabilizing Aetna: What's Driving It?

CVS makes progress in stabilizing Aetna with leadership, risk management and operational changes.

Bank of America (BofA) raised its price target on Humana to $330 from $312 on Tuesday, pointing to improved sentiment in the managed care sector following UnitedHealth’s preliminary Medicare Advantage Star Ratings update.&nbsp;The bank’s research arm&nbsp;maintained a ‘Neutral’ rating on Humana shares,&nbsp;which rose on Wednesday following the worst one-day drop in over a year in the previous session after reports suggested that the cut points for the 2026 Medicare Advantage Stars Ratings, due for official release in October, will be more stringent.Analyst Kevin Fischbeck said UnitedHealth’s stronger-than-expected ratings data prompted BofA to assign a higher peer multiple to Humana. However, he cautioned that uncertainty over 2027 Medicare Advantage rates could delay the company’s earnings recovery.Meanwhile, analysts at Raymond James said the latest news about ratings "potentially pours cold water" on hopes that Humana could win back some of its lost ratings in 2026, a year earlier than management had guided. The research firm stated that the stock "was getting a little ahead of itself" following its surge from the year's nadir in July. Still, Raymond James sees the pullback as a buying opportunity, reaffirming its 'Outperform' rating and arguing that Humana's implied 2028 valuation now stands at just 6.7 times its earnings per share.&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/united-health-fuels-bullish-mood-with-4-month-high-close-as-medicare-star-ratings-reaffirmed-2025-outlook-ease-investor-fears/chwjCVnRdM9">UnitedHealth said about 78% of its members</a> are expected to be in plans rated four stars or higher for Star Year 2026, an improvement from last year and in line with historical averages.&nbsp;The insurer reaffirmed its 2025 adjusted earnings outlook of at least $16 per share, on revenue between $445.5 billion and $448 billion, including its recent&nbsp;acquisition of Amedisys.Wall Street analysts said the update was “better than feared,” even as tougher Consumer Assessment of Healthcare Providers and Systems (CAHPS) cut points raised the bar.&nbsp;Truist raised its target on UnitedHealth to $365 from $310 with a ‘Buy’ rating, while JPMorgan and Barclays reiterated ‘Overweight’ calls, saying the disclosure should ease investor concerns. Leerink, which kept an ‘Outperform’ rating, said the performance was notable given that 58% of 2026 measures were tougher.The preliminary disclosure, covering Star Year 2026 and Payment Year 2027, is a key driver of future Medicare Advantage reimbursements.&nbsp;On Stocktwits, retail sentiment was 'extremely bullish' for Humana amid 'extremely high' message volume, while it was 'bullish' for UnitedHealth with 'high' volume.So far this year,&nbsp;<a href="https://stocktwits.com/symbol/HUM">Humana’s stock</a> has risen 8.6%, while&nbsp;<a href="https://stocktwits.com/symbol/UNH">UnitedHealth’s stock</a>&nbsp;has declined 30.7% over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

The MyHumana app page is displayed on a smartphone in the Apple App Store in front of the Humana Inc logo on October 30, 2024 in Chongqing, China. (Photo by Cheng Xin/Getty Images)

Humana Stock In Focus: BofA Raises Price Target After UnitedHealth Stars Data, Raymond James Sees Buying Opportunity

The brokerage lifted its price target on Humana to $330 but kept a ‘Neutral’ rating, citing lingering uncertainty over 2027 Medicare Advantage rates.

UnitedHealth Finds Its Stars, Soars 8.6% as Humana Trips on Cut Points

UNH surges 8.6% as it projects stable Medicare Advantage star ratings, easing investor worries over performance.

The Zacks Analyst Blog Highlights Nebius, Microsoft, UnitedHealth, Apple and Oracle

Nebius, Microsoft, UnitedHealth, Apple, and Oracle drive market buzz as AI deals, Medicare gains, and cloud growth shake up stocks.

Stock Market News for Sep 10, 2025

Wall Street closed higher on Tuesday, driven by utilities and healthcare stocks.

UnitedHealth shares closed up nearly 9%&nbsp;at a nearly four-month high on Tuesday after Wall Street analysts said&nbsp;the health insurer’s preliminary Medicare Advantage star ratings came in better than feared, even as industry benchmarks for Stars grew tougher.The insurer said about 78% of its members are expected to be in plans rated four stars or higher for Star Year 2026, up from last year and consistent with historical averages.&nbsp;UnitedHealth also reaffirmed its 2025 adjusted earnings outlook,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/unitedhealth-announces-disappointing-full-year-guidance-q2-earnings/cho9MXLR5Uo">first issued in July</a>, when it forecast revenue of $445.5 billion to $448.0 billion and adjusted earnings of at least $16 per share, down from $27.66 in 2024. The guidance includes the recently closed acquisition of Amedisys.Leerink said the disclosure was “better than feared,” highlighting UnitedHealth’s performance despite tougher Consumer Assessment of Healthcare Providers and Systems (CAHPS) cut points and new weighting factors. The&nbsp;research firm, which&nbsp;maintained an ‘Outperform’ rating, also noted that UnitedHealth appeared to have broken from the traditional ‘embargo period,’ where plans typically hold ratings details until official publication by the Centers for Medicare &amp; Medicaid Services (CMS).Truist raised its price target on the stock to $365 from $310 while maintaining a ‘Buy’ rating, calling the update a “solid” first look at 2026.&nbsp;JPMorgan analyst Lisa Gill reiterated an ‘Overweight’ rating, writing that the data was “likely better than some investors feared,” while Barclays kept an ‘Overweight’ stance with a $352 target, saying the news “should help alleviate investor concerns” and reinforced its thesis of multi-year margin improvement.Leerink added that CMS released cut points for Star Year 2026 and Payment Year 2027 through the HPMS system on Monday night, which is how UnitedHealth was able to disclose its percentages ahead of a conference presentation. “It is possible that if UNH did better, someone could have done worse,” Mayo wrote, noting that cut points overall looked “challenged.”Hyperlift’s Phillip Collins, in a&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.linkedin.com/posts/activity-7371216302113431552-uY54/?utm_source&amp;#61;share&amp;utm_medium&amp;#61;member_desktop&amp;rcm&amp;#61;ACoAABXrWbQBsbu0mnmdP2RjAc2t4fwWighMA3I">LinkedIn post</a>, said the 2026 cut points represented “another hard year,” noting that 58% of the measures got harder, 17% easier and 25% stayed the same.&nbsp;Pharmacy measures were especially difficult, with 15 cut points getting tougher and only one easing. Collins said technical specifications also showed declines in colorectal screening measures due to the transition to electronic clinical data systems.UnitedHealth’s preliminary disclosure applies to Star Year 2026 and impacts payment year 2027, a key driver of future Medicare Advantage reimbursements.&nbsp;On Stocktwits, retail sentiment for UnitedHealth&nbsp;flipped to ‘bullish’ late Tuesday, versus ‘bearish’ a day ago, amid&nbsp;a 181% spike in 24-hour&nbsp;message volume.<a href="https://stocktwits.com/symbol/UNH">UnitedHealth’s stock</a> has declined 30.4% so far in 2025,&nbsp;weighing heavily on the Dow Jones Industrial Average and making it among the worst S&amp;P 500 performers this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the UnitedHealth Group logo is displayed on the screen of a smartphone. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

UnitedHealth Fuels Bullish Mood With 4-Month High Close As Medicare Star Ratings, Reaffirmed 2025 Outlook Ease Investor Fears

Analysts also noted UNH broke from the usual “embargo period” by releasing preliminary ratings before CMS publishes official data.

UnitedHealth Reaffirms 2025 EPS Guidance: Time to Buy or Wait?

UNH reaffirms its 2025 EPS outlook, but mounting costs, legal probes and valuation pressures cloud the path ahead.

UnitedHealth Group Inc. (UNH) announced on Tuesday that it expects enrollment in its top-rated Medicare plans to be in line with expectations and historical trends.In a filing with the U.S. Securities and Exchange Commission on Tuesday, UnitedHealth stated that it estimates 78% of its memberships will be in four-star or higher-rated plans in its portfolio.<a href="https://stocktwits.com/symbol/UNH">UNH stock</a> soared more than 4% in Tuesday’s pre-market trade. Retail sentiment on Stocktwits around the company trended in the ‘bearish’ territory.While the data for 2026 star ratings provided by the Centers for Medicare &amp; Medicaid Services (CMS) is not yet available, UnitedHealth has made an estimate based on its preliminary review. The insurer also reaffirmed its adjusted earnings per share (EPS) expectations for 2025.Stocktwits data indicates that UnitedHealth is expected to report EPS of $2.81 on revenue of $113 billion in the third quarter (Q3). For the full fiscal year 2025, UNH’s EPS is expected to come in at $16.23, down from the 2024 EPS of $27.6. Revenue is expected to rise to $448 billion in 2025, from $401 billion in 2024.Senators Elizabeth Warren and Ron Wyden recently&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/elizabeth-warren-ron-wyden-blast-united-health-for-hardball-loan-tactics-tied-to-healthcare-unit-s-ransomware-breach/chtR62xRdZe">criticized</a> UnitedHealth over the company’s “hardball” tactics to recoup emergency loans issued to healthcare providers following a February 2024 ransomware attack that hit the health insurer’s Change Healthcare unit.UnitedHealth said it lent more than $9 billion under the Temporary Funding Assistance Program to providers struggling during the cyberattack. Warren called UNH’s repayment demands “deeply troubling.”<a href="https://stocktwits.com/symbol/UNH">UNH stock</a> is down 37% year-to-date and 46% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dow-futures-edge-lower-ahead-revised-jobs-data/chwKc35RdsC">Dow Futures Edge Lower As Wall Street Cautiously Awaits Revised Jobs Data: AAPL, WOLF, ASML, CASY Among Stocks To Watch</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Is UNH Stock Rising Today?

In an SEC filing on Tuesday, UnitedHealth stated that it estimates 78% of its memberships will be in four-star or higher-rated plans in its portfolio.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Current Price	$353.00
Prev Close	$351.39
Open	$353.67
Dividend Yield	1.62%
50-Day Moving Average	$292.01
Beta	0.29
Avg. Volume	19.9M
PE Ratio	15.27

52-Week High	$630.73
52-Week Low	$234.60
Market Capitalization	$319.26B
EPS (Annual)	$15.51
Price to Book	3.37
Revenue Per Employee	$1M
Enterprise Value/EBITDA	N/A

UNH
Unitedhealth Group Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest UNH News

UNH Unitedhealth Group Inc